Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT.
Ostronoff
F
F
Perales
M-A
MA
Stubblefield
M D
MD
Hsu
K C
KC
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D020275:Guillain-Barre Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D004854:Herpesvirus 4, Human / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D014184:Transplantation, Homologous; D014766:Viremia / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab